PressJanuary 24, 2024 Awakn Life Sciences Completes Successful Investigative Study to Establish Dissociative Effect of a Proprietary Sublingual S-Ketamine Oral Thin Film Formulation in Harmful Drinkers
PressJanuary 23, 2024 Red Light Holland’s Homogenized Psilocybin Microdosing Capsules Complete Product Specification Document by cGMP Pharmaceutical Company CCrest Laboratories, Provided to NUBU Pharmaceuticals in Australasia
PressJanuary 23, 2024 Cybin Announces FDA Clearance to Initiate a Phase 2a Study of CYB004 in Generalized Anxiety Disorder
PressJanuary 23, 2024 Newcourt Acquisition Corp Announces Continuation of Business Combination Close Process
Market ResearchJanuary 19, 2024 Review of the Psychedelic Industry in 2023: A Year of Toil, Torment, and Triumph
PressJanuary 19, 2024 Optimi Health Secures Amendment to Increase Quantities Of MDMA, MDA, And 2C-B Under Controlled Drugs And Substances Dealer’s Licence
PressJanuary 18, 2024 Incannex Completes Dosing and Therapy in Phase 2 “PsiGAD” Clinical Trial Assessing Psilocybin-assisted Psychotherapy for Generalized Anxiety Disorder; Data Analysis Commences
PressJanuary 18, 2024 Clearmind Medicine Inc. Selects Aegis Capital Corp. as Sole Bookrunner for $2.4M Private Placement
PressJanuary 17, 2024 Filament Health Completes the First Export of Botanical Psilocybin to Australia
PressJanuary 17, 2024 Incannex Receives IRB Approval for the RePOSA Phase 2/3 Clinical Trial Protocol to Assess IHL-42X Drug in Patients with Obstructive Sleep Apnea
PressJanuary 17, 2024 MAPS Unveils Improved Fiscal Sponsorship Program, Empowering Innovators in the Psychedelic Movement
LifestyleJanuary 16, 2024 Webinar: Healing October 7th – Using MDMA for PTSD in Israel (Presented by MAPS Israel)
PressJanuary 16, 2024 Psyence Group Inc Subsidiary Psyence Biomedical Ltd. announces signing of definitive agreement for a convertible note in connection with planned business combination
PressJanuary 16, 2024 Red Light Holland Receives Building Permit for AEM Farms 80,000 Square Foot Mushroom Farm, Adding Substantial Future Production Capacity
PressJanuary 11, 2024 PSYC’s CEO Provides Detailed Update on the State of the Company in Newly Released Podcast Recording
PressJanuary 11, 2024 Cybin Announces Positive Topline Data from Phase 1 Studies of Proprietary Deuterated DMT Molecules CYB004 and SPL028
PressJanuary 11, 2024 Algernon Pharmaceuticals Announces Notice of Allowance for Ifenprodil Patent in Japan for Idiopathic Pulmonary Fibrosis
